[go: up one dir, main page]

MX2019006830A - Compuestos de 7-feniletilamino-4h-pirimido[4,5-d] [1,3] -oxazin-2-ona como mutantes idh1 e inhibidores de idh2. - Google Patents

Compuestos de 7-feniletilamino-4h-pirimido[4,5-d] [1,3] -oxazin-2-ona como mutantes idh1 e inhibidores de idh2.

Info

Publication number
MX2019006830A
MX2019006830A MX2019006830A MX2019006830A MX2019006830A MX 2019006830 A MX2019006830 A MX 2019006830A MX 2019006830 A MX2019006830 A MX 2019006830A MX 2019006830 A MX2019006830 A MX 2019006830A MX 2019006830 A MX2019006830 A MX 2019006830A
Authority
MX
Mexico
Prior art keywords
phenylethylamino
pyrimido
oxazin
compounds
mutant idh1
Prior art date
Application number
MX2019006830A
Other languages
English (en)
Other versions
MX385562B (es
Inventor
Paul Burkholder Timothy
Alejandro Bauer Renato
Louis Boulet Serge
Gilmour Raymond
James Hahn Patric
Rankovic Zoran
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2019006830A publication Critical patent/MX2019006830A/es
Publication of MX385562B publication Critical patent/MX385562B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Un compuesto, como se define en la presente, o composición farmacéutica que contiene el compuesto, para usar en el tratamiento del cáncer mutante de IDH1 o IDH2 y que tiene la estructura: (formula).
MX2019006830A 2016-12-16 2017-12-08 Compuestos de 7-feniletilamino-4h-pirimido[4,5-d] [1,3] -oxazin-2-ona como mutantes idh1 e inhibidores de idh2. MX385562B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662435283P 2016-12-16 2016-12-16
PCT/US2017/065246 WO2018111707A1 (en) 2016-12-16 2017-12-08 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant idh1 and idh2 inhibitors

Publications (2)

Publication Number Publication Date
MX2019006830A true MX2019006830A (es) 2019-08-22
MX385562B MX385562B (es) 2025-03-18

Family

ID=60888651

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006830A MX385562B (es) 2016-12-16 2017-12-08 Compuestos de 7-feniletilamino-4h-pirimido[4,5-d] [1,3] -oxazin-2-ona como mutantes idh1 e inhibidores de idh2.

Country Status (37)

Country Link
US (3) US11001596B2 (es)
EP (2) EP3763717B1 (es)
JP (1) JP6793836B2 (es)
KR (1) KR102276022B1 (es)
CN (2) CN110072867B (es)
AU (2) AU2017378060B2 (es)
CA (1) CA3045303C (es)
CL (1) CL2019001551A1 (es)
CO (1) CO2019005287A2 (es)
CR (1) CR20190252A (es)
CY (1) CY1123577T1 (es)
DK (1) DK3555105T3 (es)
DO (1) DOP2019000163A (es)
EA (1) EA036112B1 (es)
EC (1) ECSP19042682A (es)
ES (2) ES2941631T3 (es)
HR (1) HRP20201882T1 (es)
HU (1) HUE052067T2 (es)
IL (1) IL267236B (es)
JO (1) JOP20190142B1 (es)
LT (1) LT3555105T (es)
MA (2) MA47399B1 (es)
MD (1) MD3555105T2 (es)
MX (1) MX385562B (es)
MY (1) MY197313A (es)
NZ (1) NZ754115A (es)
PE (1) PE20190977A1 (es)
PH (1) PH12019501328B1 (es)
PL (1) PL3555105T3 (es)
PT (1) PT3555105T (es)
RS (1) RS61108B1 (es)
SA (1) SA519401897B1 (es)
SI (1) SI3555105T1 (es)
TN (1) TN2019000158A1 (es)
UA (1) UA123640C2 (es)
WO (1) WO2018111707A1 (es)
ZA (1) ZA201903125B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2961793C (en) 2014-09-19 2021-03-16 Forma Therapeutics, Inc. Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
PT3194376T (pt) 2014-09-19 2019-02-04 Forma Therapeutics Inc Derivados da piridin-2(1h)-ona-quinolinona como inibidores da isocitrato-desidrogenase mutante
EP3194375B1 (en) 2014-09-19 2018-11-21 Forma Therapeutics, Inc. Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
ES2706525T3 (es) 2014-09-19 2019-03-29 Forma Therapeutics Inc Derivados de piridinilquinolinona como inhibidores de isocitrato deshidrogenasa mutante
US10294206B2 (en) 2015-04-21 2019-05-21 Forma Tm2, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
US10407419B2 (en) 2015-04-21 2019-09-10 Forma Therapeutics, Inc. Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
PL3640251T3 (pl) 2016-10-24 2022-04-11 Astrazeneca Ab Pochodne 6,7,8,9-tetrahydro-3H-pirazolo[4,3-f]izochinoliny przydatne w leczeniu nowotworu złośliwego
PE20191105A1 (es) 2016-12-16 2019-08-23 Janssen Pharmaceutica Nv Inhibidores de moleculas pequenas de lafamilia de quinasas jak
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
EA036112B1 (ru) * 2016-12-16 2020-09-29 Эли Лилли Энд Компани 7-фенилэтиламино-4h-пиримидо[4,5-d][1,3]оксазин-2-оновые соединения в качестве ингибиторов мутантных idh1 и idh2
MY196317A (en) 2017-01-30 2023-03-24 Astrazeneca Ab Estrogen Receptor Modulators
US11311527B2 (en) 2018-05-16 2022-04-26 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
WO2019222553A1 (en) 2018-05-16 2019-11-21 Forma Therapeutics, Inc. Inhibiting mutant idh-1
WO2019222551A1 (en) 2018-05-16 2019-11-21 Forma Therapeutics, Inc. Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
US11013733B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
US11013734B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
CN115038700B (zh) * 2019-11-08 2025-07-25 内尔维亚诺医疗科学公司 偕二取代的杂环化合物及其作为idh抑制剂的用途
WO2021194950A1 (en) 2020-03-23 2021-09-30 Eli Lilly And Company Combination therapy with a mutant idh inhibitor and a bcl-2 inhibitor
AU2021242260B2 (en) * 2020-03-23 2023-12-14 Eli Lilly And Company Combination therapy with a mutant IDH inhibitor
JP7462789B2 (ja) * 2020-03-23 2024-04-05 イーライ リリー アンド カンパニー Ｉｄｈ１阻害剤耐性対象の治療方法
WO2021214253A1 (en) 2020-04-24 2021-10-28 Astrazeneca Ab Dosage regimen for the treatment of cancer
IL297218A (en) 2020-04-24 2022-12-01 Astrazeneca Ab Pharmaceutical formulations
US20230174550A1 (en) * 2020-06-28 2023-06-08 Wigen Biomedicine Technology (shanghai) Co., Ltd. Idh mutant inhibitor and use thereof
US20230255973A1 (en) * 2020-07-20 2023-08-17 Eli Lilly And Company Combination therapy with a mutant idh1 inhibitor, a deoxyadenosine analog, and a platinum agent
EP4304590A1 (en) 2021-03-11 2024-01-17 Janssen Pharmaceutica NV Lorpucitinib for use in the treatment of jak mediated disorders
CN113588768B (zh) * 2021-05-18 2022-07-05 国家卫生健康委科学技术研究所 一种以分子图像方式定量组织内内源性代谢物的质谱方法
JP2024520854A (ja) 2021-06-09 2024-05-24 イーライ リリー アンド カンパニー Ｉｄｈ阻害剤耐性の対象を治療する方法
US20240208978A1 (en) 2021-06-15 2024-06-27 Wigen Biomedicine Technology (shanghai) Co., Ltd. Idh mutant inhibitor and use thereof
US11746115B2 (en) 2021-08-13 2023-09-05 Eli Lilly And Company Solid forms of 7-[[(1S)-1-[4-[(1S)-2-cyclopropyl-1-(4-prop-2-enoylpiperazin-1-yl)ethyl]phenyl]ethyl]amino]-1-ethyl-4H-pyrimido[4,5-d][1,3]oxazin-2-one
WO2023141087A1 (en) 2022-01-19 2023-07-27 Eli Lilly And Company Combination therapy with a mutant idh inhibitor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013046136A1 (en) * 2011-09-27 2013-04-04 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
WO2014141153A1 (en) * 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
WO2014147586A1 (en) * 2013-03-22 2014-09-25 Novartis Ag 1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh
US10294206B2 (en) * 2015-04-21 2019-05-21 Forma Tm2, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
CN107405687A (zh) * 2015-04-24 2017-11-28 哈利伯顿能源服务公司 制作陶瓷或金属间化合物零件的方法
US10253041B2 (en) * 2015-07-27 2019-04-09 Eli Lilly And Company 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds and their use as mutant IDH1 inhibitors
JP6682043B2 (ja) * 2016-06-06 2020-04-15 イーライ リリー アンド カンパニー 変異体ｉｄｈ１阻害剤
EA036112B1 (ru) * 2016-12-16 2020-09-29 Эли Лилли Энд Компани 7-фенилэтиламино-4h-пиримидо[4,5-d][1,3]оксазин-2-оновые соединения в качестве ингибиторов мутантных idh1 и idh2

Also Published As

Publication number Publication date
PT3555105T (pt) 2020-12-21
CL2019001551A1 (es) 2019-10-25
CO2019005287A2 (es) 2019-05-31
AU2020260493B2 (en) 2021-09-09
EP3555105B1 (en) 2020-10-28
EP3763717A1 (en) 2021-01-13
MA47399B1 (fr) 2021-02-26
IL267236B (en) 2020-08-31
UA123640C2 (uk) 2021-05-05
JP6793836B2 (ja) 2020-12-02
AU2020260493A1 (en) 2020-11-26
EA201991161A1 (ru) 2019-11-29
AU2017378060B2 (en) 2020-09-03
PE20190977A1 (es) 2019-07-09
EP3763717B1 (en) 2023-03-08
CN115109075B (zh) 2024-09-20
PH12019501328A1 (en) 2020-02-24
CY1123577T1 (el) 2022-03-24
MA53881A (fr) 2022-04-27
DOP2019000163A (es) 2019-07-15
CA3045303A1 (en) 2018-06-21
US20200079791A1 (en) 2020-03-12
US11001596B2 (en) 2021-05-11
US20210206780A1 (en) 2021-07-08
ES2835281T3 (es) 2021-06-22
NZ754115A (en) 2021-07-30
JOP20190142B1 (ar) 2023-03-28
US11649247B2 (en) 2023-05-16
JOP20190142A1 (ar) 2019-06-13
AU2017378060A1 (en) 2019-05-30
MY197313A (en) 2023-06-13
HRP20201882T1 (hr) 2021-01-22
SA519401897B1 (ar) 2022-07-28
EP3555105A1 (en) 2019-10-23
CN110072867A (zh) 2019-07-30
WO2018111707A1 (en) 2018-06-21
TN2019000158A1 (en) 2020-10-05
KR102276022B1 (ko) 2021-07-13
CN115109075A (zh) 2022-09-27
MX385562B (es) 2025-03-18
ES2941631T3 (es) 2023-05-24
CR20190252A (es) 2019-08-26
BR112019009648A2 (pt) 2019-09-10
HUE052067T2 (hu) 2021-04-28
MA47399A (fr) 2019-10-23
US20210230185A1 (en) 2021-07-29
CA3045303C (en) 2022-05-17
MD3555105T2 (ro) 2021-01-31
LT3555105T (lt) 2021-01-11
ZA201903125B (en) 2024-08-28
ECSP19042682A (es) 2019-06-30
KR20190077539A (ko) 2019-07-03
JP2020502157A (ja) 2020-01-23
PL3555105T3 (pl) 2021-05-17
RS61108B1 (sr) 2020-12-31
US11629156B2 (en) 2023-04-18
IL267236A (en) 2019-08-29
PH12019501328B1 (en) 2023-05-12
EA036112B1 (ru) 2020-09-29
SI3555105T1 (sl) 2020-12-31
DK3555105T3 (da) 2020-11-09
CN110072867B (zh) 2022-07-08

Similar Documents

Publication Publication Date Title
MX2019006830A (es) Compuestos de 7-feniletilamino-4h-pirimido[4,5-d] [1,3] -oxazin-2-ona como mutantes idh1 e inhibidores de idh2.
ECSP18094983A (es) Derivados de pirazol como inhibidores de la calicreína plasmática
GEAP202215540A (en) Pcsk9 antagonist compounds
MX2018011992A (es) Compuestos de aminopurina sustituida, composiciones de estos y metodos de tratamiento con estos.
CL2009000483A1 (es) Compuestos derivados de n-(piridin-3-il)-1,3-tiazol-5-amino-4-carboxamida, inhibidores de cinasa pim; composicion farmaceutica; y uso para el tratamiento del cancer.
BR112018004620A2 (pt) moduladores da expressão de kras
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
CL2011000454A1 (es) Compuestos derivados de picolinamida, inhibidores de quinasa pim, asociada a tumorigenesis; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
NI200900184A (es) Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer.
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
DOP2016000208A (es) Benzimidazol-2-aminas como inhibidores de midh1
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
MX2017004600A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
CO2022000481A2 (es) Inhibidores de enzimas
NZ758177A (en) Modulators of pcsk9 expression
DOP2020000100A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
CO2022000270A2 (es) Inhibidores de enzimas
MX2016010524A (es) Derivados de piridazina para uso en la prevencion o tratamiento de trastorno ataxico.
CR20150148A (es) Azaindolinas
CL2011000168A1 (es) Compuestos derivados de narciclasina y pancratistatina; procedimiento de preparación; composición farmacéutica; combinación farmacéutica; y su uso para el tratamiento del cáncer.
UY38472A (es) Moduladores de la expresión de foxp3